Pharmacogenetic polymorphisms affecting bisoprolol response

Castaño-Amores, C; Díaz-Villamarín, Xando; Pérez-Gutiérrez, Ana María; Antúnez-Rodríguez, Alba; Pozo-Agundo, Ana; Moreno‐Escobar, Eduardo; Sánchez-Ramos, Jesús; Martínez-González, Luis Javier; Dávila-Fajardo, Cristina Lucía

doi:10.1016/j.biopha.2021.112069

Cited by 7 publications

(6 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Importantly, two genome-wide significant loci were identified, with the lead SNP rs11029955 also shown to be associated with HR reduction in an independent validation cohort comprising individuals with hypertension. Interestingly, no associations were found using individual pharmacogenetic variants, nor genotype-based metabolizer phenotypes, in the two main enzymes involved in bisoprolol metabolism, CYP2D6 and CYP3A, consistent with the systematic review of Castano-Amores et al 22 …”

Section: Discussionsupporting

confidence: 86%

“…The systematic review of bisoprolol pharmacogenetics showed that β-adrenoceptor genotypes ( ADRB1 and ADRB2 ) have been the most widely studied, but the results have been contradictory. 22 No association was found with these genes in our study. Interestingly in the GENRES study, 8 polymorphisms in ACY3 (aminoacylase III) on chromosome 11 were significantly associated with the extent of blood pressure lowering with bisoprolol.…”

Section: Discussioncontrasting

confidence: 74%

“…A recent systematic review and meta-analysis of pharmacogenetic studies undertaken with bisoprolol did not show convincing evidence of associations with either PK or PD genes, with the authors concluding that there is a “need of further studies about the impact of genetic variants on bisoprolol response” 22 . We have risen to this challenge, and to the best of our knowledge, our study represents the first GWAS of bisoprolol PK, based on bisoprolol clearance estimated by Pop-PK modeling.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Chromosomal Region 11p14.1 is Associated with Pharmacokinetics and Pharmacodynamics of Bisoprolol

Fontana

Turner

Francis

et al. 2022

PGPM

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 86%

Section: Discussioncontrasting

confidence: 74%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Chromosomal Region 11p14.1 is Associated with Pharmacokinetics and Pharmacodynamics of Bisoprolol

Fontana

Turner

Francis

et al. 2022

PGPM

View full text Add to dashboard Cite

“…As an example, in previous versions of the manual method, we classified bisoprolol as a CYP2D6 substrate, which resulted in a major difference in the CYP2D6 classification. While the drug metoprolol is unquestionably a CYP2D6 substrate, studies for bisoprolol were in the past not as clear [22]. Bisoprolol seems to be metabolized to a small extent by CYP2D6, but the clinical impact of CYP2D6 PGx variants on the efficacy and safety of bisoprolol is unlikely [23].…”

Section: Discussionmentioning

confidence: 99%

Assessment of Substrate Status of Drugs Metabolized by Polymorphic Cytochrome P450 (CYP) 2 Enzymes: An Analysis of a Large-Scale Dataset

Sommer,

Wozniak,

Schmitt

et al. 2024

Biomedicines

View full text Add to dashboard Cite

Background: The analysis of substrates of polymorphic cytochrome P450 (CYP) enzymes is important information to enable drug–drug interactions (DDIs) analysis and the relevance of pharmacogenetics in this context in large datasets. Our aim was to compare different approaches to assess the substrate properties of drugs for certain polymorphic CYP2 enzymes. Methods: A standardized manual method and an automatic method were developed and compared to assess the substrate properties for the metabolism of drugs by CYP2D6, 2C9, and 2C19. The automatic method used a matching approach to three freely available resources. We applied the manual and automatic methods to a large real-world dataset deriving from a prospective multicenter study collecting adverse drug reactions in emergency departments in Germany (ADRED). Results: In total, 23,878 medication entries relating to 895 different drugs were analyzed in the real-world dataset. The manual method was able to assess 12.2% (n = 109) of drugs, and the automatic method between 12.1% (n = 109) and 88.9% (n = 796), depending on the resource used. The CYP substrate classifications demonstrated moderate to almost perfect agreements for CYP2D6 and CYP2C19 (Cohen’s Kappa (κ) 0.48–0.90) and fair to moderate agreements for CYP2C9 (κ 0.20–0.48). Conclusion: A closer look at different classifications between methods revealed that both methods are prone to error in different ways. While the automated method excels in time efficiency, completeness, and actuality, the manual method might be better able to identify CYP2 substrates with clinical relevance.

show abstract

“…Furthermore, the majority of human studies examining the functional implications of these polymorphisms have primarily centered around metoprolol, atenolol and carvedilol [ 18–21 ]. However, the investigations on genetic variants influencing bisoprolol response are limited and perplexing [ 22 ]. Additionally, many of these studies failed to consider the potential impact of prior beta blocker exposure, leading to confounding factors due to the lingering antihypertensive effects [ 23 ].…”

mentioning

confidence: 99%

β1-Adrenergic Receptor Polymorphisms: A Possible Genetic Predictor of Bisoprolol Response in Acute Coronary Syndrome

Fayed,

Saleh,

Sabri

et al. 2023

Future Sci. OA

View full text Add to dashboard Cite

Aim: To investigate the association between beta1-adrenergic receptor ( ADRB1) polymorphisms and response to bisoprolol treatment in beta-blocker naive patients with acute coronary syndrome (ACS). Patients & methods: Seventy-seven patients received bisoprolol for four weeks. Blood pressure and heart rate were measured at baseline and during treatment. TaqMan allelic discrimination method was utilized for ADRB1 Ser49Gly and Arg389Gly genotyping. Results: Arg389Arg carriers showed greater reductions in systolic and diastolic blood pressure (-8.5% ± 7.8% vs -0.76% ± 8.7%, p = 0.000218), and (-9.5% ± 9.7% vs -0.80% ± 11.5%, p = 0.000149), respectively, compared with Gly389 carriers. No statistical difference was found for study's outcomes based on codon 49. Conclusion: Arg389Gly polymorphism is a promising bisoprolol response predictor in ACS patients.

show abstract

Pharmacogenetic polymorphisms affecting bisoprolol response

Cited by 7 publications

References 43 publications

Chromosomal Region 11p14.1 is Associated with Pharmacokinetics and Pharmacodynamics of Bisoprolol

Chromosomal Region 11p14.1 is Associated with Pharmacokinetics and Pharmacodynamics of Bisoprolol

Assessment of Substrate Status of Drugs Metabolized by Polymorphic Cytochrome P450 (CYP) 2 Enzymes: An Analysis of a Large-Scale Dataset

β1-Adrenergic Receptor Polymorphisms: A Possible Genetic Predictor of Bisoprolol Response in Acute Coronary Syndrome

Contact Info

Product

Resources

About